Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
https://www.zacks.com/stock/news/2227421/ultragenyx-rare-q4-loss-narrower-than-expected-revenues-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-2227421
Feb 16, 2024 - Ultragenyx (RARE) reports better-than-expected fourth-quarter 2023 results, beating both earnings and revenue estimates, driven by strong sales trends of Crysvita and Dojolvi.
0
2 No-Brainer Biotech Stocks to Buy Right Now
https://www.fool.com/investing/2024/02/21/2-no-brainer-biotech-stocks-to-buy-right-now/?source=iedfolrf0000001
Feb 21, 2024 - These stocks are used to beating the market.
0
EXEL vs. REGN: Which Stock Is the Better Value Option?
https://www.zacks.com/stock/news/2236830/exel-vs-regn-which-stock-is-the-better-value-option?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2236830
Mar 06, 2024 - EXEL vs. REGN: Which Stock Is the Better Value Option?
0
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
https://www.zacks.com/stock/news/2239307/aslan-asln-up-161-on-upbeat-initial-data-from-eczema-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2239307
Mar 12, 2024 - ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with eczema, who have previously been treated with Dupixent but did not achieve an adequate response.
0
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
https://www.zacks.com/stock/news/2240974/biotech-stock-roundup-amlx-acad-down-on-study-data-mrna-rgls-gain-on-updates-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2240974
Mar 14, 2024 - Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.
0
Top Research Reports for JPMorgan Chase, Merck & SAP
https://www.zacks.com/commentary/2243512/top-research-reports-for-jpmorgan-chase-merck-sap?cid=CS-ZC-FT-research_daily-2243512
Mar 20, 2024 - Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Merck & Co., Inc. (MRK) and SAP SE (SAP).
0
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
https://www.fool.com/investing/2024/03/28/stock-split-watch-are-these-2-top-growth-stocks/?source=iedfolrf0000001
Mar 28, 2024 - Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense.
0
Why Regeneron (REGN) Could Beat Earnings Estimates Again
https://www.zacks.com/stock/news/2256270/why-regeneron-regn-could-beat-earnings-estimates-again?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2256270
Apr 16, 2024 - Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
0
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
https://www.zacks.com/stock/news/2257993/biotech-stock-roundup-regn-sage-nmra-down-on-updates-itci-gains-on-study-success?cid=CS-ZC-FT-analyst_blog|stock_roundup-2257993
Apr 18, 2024 - Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.
0
EXEL vs. REGN: Which Stock Is the Better Value Option?
https://www.zacks.com/stock/news/2262530/exel-vs-regn-which-stock-is-the-better-value-option?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2262530
Apr 25, 2024 - EXEL vs. REGN: Which Stock Is the Better Value Option?
0
<Page 2